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INTRODUCTION
Two are the main goals of the treatment for cholesteatoma are the eradication of disease and prevention of its recurrence. The canal wall 
down (CWD) technique has traditionally been associated with quite a low recurrence rate [1]. However, this surgical procedure has many 
disadvantages associated with the persistent mastoid bowl (open tympanomastoid cavity); a large cavity may cause chronic ear discharge 
not responding to pharmaceutical agents, vertigo on exposure to water, and exhibit a tendency of debris accumulation in the mastoid 
cavity that requires frequent cleaning [1]. Moreover, patients with compromised hearing loss are unable to wear traditional hearing aids. 
One of the main surgical interventions used for the treatment of an open mastoid cavity and all the related problems is mastoid oblitera-
tion. Two are the types of materials used for mastoid obliteration: biological (autologous grafts, allografts, and xenografts) and synthetic [2]. 
Biological materials are the best option for mastoid obliteration and reconstruction of the posterior ear canal, but they have disadvantages 
such as resorption, atrophy, difficulty in fashioning, and donor site morbidity. It is often challenging to find enough material because of 
the number of previous operations [3-4]. To address these problems, artificial materials such as bioactive glass (BAG), hydroxyapatite (HA), 
titanium, and silicone have been introduced [5-7]. Benefits of synthetic materials are that they are easy to use, uncontaminated, and theoret-
ically endlessly available [8]. Moreover, they save considerable time in the operative technique, as minimal or no meatoplasty is required [9].
The objective of this review is to evaluate the effectiveness of mastoid obliteration using synthetic materials in patients who under-
went CWD mastoidectomy and to discuss the literature regarding the types of available materials for this reason. 
MATERIALS AND METHODS
We searched Web of Science, PubMed, and MEDLINE databases from 2008 to 2018 for original articles and case series concerning 
the mastoid obliteration with synthetic materials in CWD mastoidectomy. Only articles in English were reviewed. 
Canal wall down mastoidectomy is a surgical technique used for the eradication of middle ear disease. The remaining large mastoid bowl is asso-
ciated with a number of issues; one of the main techniques that have been developed in order to avoid such problems is the obliteration of the 
mastoid cavity. The materials used for this reason are either biological or synthetic. The purpose of this survey is to review the published literature 
related to the therapeutic value of mastoid obliteration with synthetic materials. We searched Web of Science, PubMed, and MEDLINE from 2008 
to 2018 using the criteria mastoid obliteration, canal wall down mastoidectomy, chronic otitis media, and cholesteatoma. The search focused on 
papers concerning the mastoid obliteration with synthetic material, as we focused on looking for outcomes and reported complications. Out of 
a total of 244 citations, 15 articles were identified, where patients underwent mastoid obliteration with synthetic materials. Most authors used 
bioactive glass as a filler material. Mastoid obliteration resulted in a decrease in the complications associated with the open mastoid cavity. On 
the basis of the available limited literature, it seems that mastoid obliteration with synthetic materials is a valuable and safe surgical technique for 
patients who undergo canal wall down mastoidectomy. The bioactive glass appears to be the most reliable synthetic material.
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The following terms were used: mastoid obliteration, CWD mastoid-
ectomy, chronic otitis media, and cholesteatoma. The limiting search 
terms were the synthetic materials. Additional articles were identi-
fied by hand searching the reference lists of the retrieved articles. 
We initially identified the papers based on their title, limited their 
number based on their abstract, and finally on the basis of the whole 
document. Two authors (C.S. and P. K.) independently classified the 
articles that were eligible. Any difference was resolved by consensus. 
The literature was analyzed regarding the type of filler material used, 
the rate of extrusion/ complications, and the effectiveness of each 
type of mastoid obliteration. This was based on the postoperative as-
sessment of complications, the shape of the external auditory canal 
as described in each study, and the improvement of hearing. 
Statistical Analysis
All the computations needed were processed by the RStudio pro-
gram (RStudio Team, 2015, RStudio: Integrated Development for R. 
RStudio, Inc., Boston, MA). The overall rate of rejection of the used 
synthetic material was computed by dividing the number of cases 
with extrusion by the total number of cases.
RESULTS
We included 15 articles that described patients who underwent mas-
toid obliteration with synthetic materials. The initial search using the 
term “mastoid cavity obliteration” brought in 244 citations, of which 
145 did not meet the inclusion criteria and 48 were not published 
in English. An additional 38 articles were excluded because they re-
ported mastoid obliteration with natural materials. The remaining 13 
studies were included in the review (Figure1). The use of search terms 
and the manual search yielded two additional studies. Thus, the total 
number of articles meeting the inclusion criteria increased to 15 (Ta-
ble1) [6, 7, 10-22]. All papers were included in a retrospective case series. 
Type of Synthetic Material
The material most authors used for the obliteration of the mastoid is 
bioactive glass (9/15 studies). S53P4 was the type of BAG that seven 
of these authors applied. Bioactive glass ceramics were chosen for 
use in two studies. The second most widely used material was hy-
droxyapatite, either in the form of a cement or in the form of granules 
(3 out of 5 studies). Other filling materials were hydroxyapatite, tita-
nium, and silicone. Some authors used a combination of biological 
and artificial materials.
Effectiveness (Efficacy)
As mentioned above, the evaluation of the effectiveness of mastoid 
obliteration was based on the postoperative assessment of com-
plications, appearance of the external auditory canal contour, and 
the improvement in hearing. In the present review, the overall rate 
of rejection of the used synthetic material was quite low (3.5% with 
a range of 0-15.8 %); the study showing 0% rejection rate included 
Table 1. Summary of articles on mastoid obliteration and associated synthetic materials in mastoidectomy surgery procedures
    Complications 
Study(Year)/    (apart from rejection 
Number of patient Material Operation Follow Up of material)
Sorour [6] (2018)/ 20  BAG (S53P4) PMW Reconstruction in CWD 12-36 months Persistent otorrhea: 2 (10%)
Elbary [10] (2018)/20 TitaniumMicromesh PMW Reconstruction in CWD 12-36 months 0
Mestdagh [11] (2017)/ 67 BAG (S53P4) MO in CWD  12-54 months Cholesteatoma recidivism: 4 (6%)
Vos [12] (2017) /23 BAG (S53P4) MO in CWD & CWU 2.4 Years Persistent otorrhea: 6 (26%)
Bernardeschi [13] (2017) /41 BAG (S53P4) MO in CWD & CWU  1 Year Granulation tissue: 1(2.4%)
Ezzat [14] (2014)/40 BAG (45S5) MO in CWD 2 Years Persistent otorrhea: 6 (15%) 
    Cholesteatoma recidivism: 4 (10%)
Lee [7] (2013)/20  HA MO in CWD 1 Year Retraction pocket: 1 (5%) 
    Infection: 1 (5%)
Silvola [15] (2012)/16 BAG (S53P4) MO in CWD 2.2 Years Infection:4 (25%)
Shokry [16] (2012)/20 BAG (45S5) MO in CWD 6 Month Infection: 2 (10%) 
    Cartilage extrusion: 1 (5%)
Sarin [17] (2012)/25 BAG (S53P4) MO in CWD  34,5 week Prolonged healing: 2 (8%)  
    Postoperative vertigo and pain: 1 (4%) 
Cho [18] (2012)/20 Silicone PMW Reconstruction  6-90 Months 0 
  & MO in CWD
Park [19] (2011)/30 HA PMW Reconstruction  6month Persistent otorrhea: 3(10%) 
  & MO in CWD & CWU  Granulation tissue: 6 (20%)
Stoor [20] (2010)/7 BAG (S53P4) MO in CWD 12-98 Months Granulation tissue: 1 (14%)
Kakigi21 (2008) /10 HA - calcium phosphate paste MO in CWD 19.9 Months 0
Ridenour22 (2008) /3 HA MO in CWD  2 y 0
vBAG: Bioactive glass; CWD: Canal wall down; CWU: Canal wall up; HA: Hydroxyapatite; MO: Mastoid obliteration; PMW: Posterior meatal wall
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only 20 patients (Table 2). Patients treated with hydroxyapatite were 
the most high-risk group for extrusion (15.8%). Apart from the rejec-
tion of the used material, the most common complication of mastoid 
obliteration was persistent otorrhea (10-25%). Other reported com-
plications include occurrence of infection (25%), persistent granula-
tion in the posterior canal wall (2.4-20%), retraction pocket formation 
(5%), and postoperative vertigo and pain (4%). In two studies, a high 
rate of cholesteatoma recidivism was reported (6% and 10%).
DISCUSSION
Herein, we looked into the use of synthetic material for mastoid oblit-
eration and its current state in the literature. The available level of evi-
dence is low (3), consisting of retrospective case series and limited clin-
ical reports. The limited number of publications is the main reason for 
this. So far, however, the use of synthetic material in mastoid oblitera-
tion appears an established way of dealing with cavities with relatively 
low complication rates. Our study did not compare biological with syn-
thetic products; as such comparisons would have been very challeng-
ing and potentially of meaningless/low-evidence conclusions. Still, it 
provides an up-to-date overview of the efficacy of synthetic material. 
Generally, in canal wall up mastoidectomy, the anatomy of the posterior 
canal wall is preserved avoiding recurrent infections and eliminating the 
need for recurrent cavity cleaning. However, this surgical technique is as-
sociated with a high recurrence rate (36% in adults and 67% in children) [1, 
23]. However, CWD mastoidectomy has numerous advantages, including 
less operative time and lower recurrence and residual rate. For all these 
reasons, it is the most widely used surgical intervention for treatment of 
cholesteatoma worldwide [24]. A large mastoid bowl after CWD mastoid-
ectomy can be associated with a number of complications, such as recur-
rent drainage and infection, water intolerance, calorically induced vertigo 
and others; [1] thus, patients may suffer a substantial loss of quality of life. 
Surgical techniques used for management of an open mastoid cavity 
after CWD mastoidectomy include obliteration (cavity fill-in) and recon-
struction (canal wall defect repair). The obliteration method includes fill-
ing the mastoid cavity with various biological (fat, bone chips) or synthet-
ic materials (bioactive glass, hydroxyapatites, titanium, or silicone). 
The use of biological materials is associated with several drawbacks, 
namely, long-term follow-up has showed that some soft tissues, such 
as free muscles, fat, and fascia flaps tend to undergo atrophy, retraction, 
and fibrosis. This leads to a progressive loss of the obliterating material 
over time. Thus, the final shape and size of the mastoid cavity cannot 
be predicted. That is why some authors recommend overfilling of the 
mastoid cavity. Another limitation of autogenous materials is the fact 
that it is difficult to have an adequate amount of them available. More-
over, harvesting an autologous graft increases the duration of surgery 
and the morbidity rate. Finally, autogenous obliteration materials are 
associated with donor site morbidity. Various artificial materials have 
been introduced to compensate for the limitations of autografts.
Table 2. Summary of the type of synthetic materials used for mastoid obliteration and percentage of rejected materials 
  
 Authors/No patients/ 
Material/Trade Νaμe/Company Cases of rejected material Total cases for each material  Total cases of extrusion
BAG (S53P4)/Bon Alive/ Bon Alive Biomaterial LDT Sorour [6] 20/0 199 1 (0.5 %) 
(Turku, Finland)  Mestdagh [11] 67/0 
 Vos [12] 23/0 
 Bernardeschi [13] 41/0 
 Silvola [15] 16 /0 
 Sarin [17] 25/1 
 Stoor [20] 7/0
BAG 45S5/CERAVITAL/. (Ernst Leitz, Wetzlar, Germany; Ezzat [14] 40/2 60 2 (3.3%) 
Xomed, Jacksonville, Fla) Shokry [16] 20/0
Hydroxyapatite (HA) or β-tricalcium phosphate and Lee [7] 20/1 63 9 (15.8%) 
polyphosphate (β-TPP)/PolyBone/Mimix ® Park [19] 30/6 
Kyoungwon Medical Co., Seoul, Korea Kakigi [21] 10/0 
 Ridenour [22] 3/3
TitaniumMicromesh,/-/JEILmedical corporation, Seoul, Korea Elbary [10] 20/0 20 0 (0%)
Silicone/-/Hansbiomed Co., Daejeon, Korea) Cho [18] 20/1 20 1 (5%) 
  362 13 (3.5%)
BAG: Bioactive glass; HA: Hydroxyapatite; β-TPP: β-tricalcium phosphate and polyphosphate
Figure 1. Flow chart of the reviewing process.
Articles identified initially through the term “mastoid cavity obliteration“ (n=244)
Articles excluded with reasonns (n=193) (non-English articles, 
reports not on mastoid cavity obliteration, case reports)
Articles excluded with reasonns (n=38) (reports on 
mastoid cavity obliteration with biological materials)
Additional studies found by hand search and 
search using the rest of the terms (n=2)
Potentially appropriate articles to 
be included in the review (n=51)
Appropriate articles to be  
included in the review (n=13)
Articles included in the 
review (n=15)
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Type of Synthetic Material
To date, numerous synthetic materials have been proposed for the oblit-
eration of the mastoid cavity. The material most authors used is bioac-
tive glass (BAG) [6, 11-17, 20]. It is one of the latest synthetic biomaterials that 
combines several advantages. Several BG types have been tested and 
each type presents different properties in vivo [25]. S53P4 and 45S5 are 
the two main BAGs that have been studied in vivo [26]. S53P4, named af-
ter its chemical composition of 53% SiO2 and 4% P2O5, has the property 
of not shrinking after obliteration. This is important for retaining an ana-
tomically suitable volume in the obliterated area. Although BAG S53P4 
is a resorbable material, it does not resorb before new bone has formed. 
On the other hand, 45S5 is characterized by a significantly faster resorp-
tion rate. S53P4 possesses antibacterial properties that minimize the risk 
of infection and decrease the extrusion of the mastoid filler. Munukka et 
al. [27] demonstrated that BAG S53P4 has a significant bactericidal effect 
on 29 clinically important aerobic bacteria, including methicillin-resis-
tant Staphylococcus aureus. Likewise, Leppäranta et al. [28] found that BAG 
S53P4 had a strong growth-inhibitory effect on 17 anaerobic bacteria. 
The safety of using BAG as mastoid filler material has been well estab-
lished in several studies. Other convincing arguments in favor of the use 
of BAG are its osteoconductive and angiogenesis promoting properties.
Another widely used biomaterial as a bone substitute is Hydroxyapatite 
(Ca10(PO4)6(OH)2). The mineral composition of hydroxyapatite (HA) is 
similar to that of bone [19]. It can be classified into two categories, namely 
Synthetic HAP and Coralline HA. HA can be used in the form of granules, 
cements, and other bone implants. The main advantages of this alloplastic 
material are good biocompatibility, good osteoconductive properties, and 
direct chemical bond formation with hard tissues [29]. However, the use of 
HA cement as a mastoid filler is associated with several complications, such 
as infection, severe osteitis, and delayed osseointegration [30]. An imperme-
able and avascular implant is at risk for foreign body reaction in the pres-
ence of any infection, even if it is delayed. On the other side, granules might 
be a reasonable obliteration material. It is their abundant porous structure 
that allows them to absorb antimicrobial solutions before implantation and 
allow vascular ingrowth in situ [22]. Additionally, a calcium phosphate paste 
was used for mastoid obliteration because of its biocompatibility and os-
teoconductivity. It fits into cavities of various sizes and enables minimally 
invasive surgery. The β-tricalcium phosphate and polyphosphate (β-TPP)/
Polybone is a kind of HA. It is available in two forms: granular and powder. It 
contains an osseointegration factor that stimulates the differentiation of os-
teoblasts and increases the expression of bone morphogenetic protein-4. 
Animal experiments demonstrated that new bone formed around obliter-
ated Polybone and showed successful osteointegration [7]. In addition, Poly-
bone causes nearly no inflammation due to its high biocompatibility. Gran-
ular Polybone produces less inflammatory reaction in comparison with the 
powder type. Although Polybone is considered a relatively safe and effec-
tive mastoid filler, the literature describing its otologic use is limited. 
Silicone is widely used in otosurgery (ventilation tubes, cochlear im-
plants, and ossiculoplasty prostheses). It is considered to be a safe 
material, as there is no evidence of immunotoxic response. Silicone 
blocks are flexible enough to handle and are suitable for different 
sized cavities. Moreover, they are strong enough to prevent break-
down in the mastoid. In addition, their cost is much lower than other 
alloplastic materials. However, the use of silicone may lead to a for-
eign body reaction [18].
Finally, Titanium is a synthetic material that has been also used for 
the management of the persistent mastoid bowl. It has been prov-
en to be biocompatible. It also has the property of osseointegration 
with bone. In addition, a titanium mesh is a pliable material, so it can 
be easily shaped according to the surgical requirements [10].
Effectiveness and Complications
Evaluation of the effectiveness of mastoid obliteration is based on 
the postoperative assessment of complications, the incidence of ex-
trusion, and the appearance of the external auditory canal. Numerous 
studies have shown good results with the use of BAG S53P4. The over-
all incidence of extrusion in this therapy group was found to be 0.5%. 
Sorour et al. [6] assessed the results of posterior meatal wall reconstruc-
tion after CWD mastoidectomy using S53P4. In all patients, the recon-
structed ear canal was smooth without hidden pouches, irregularities, 
or stenosis. No foreign body reaction, extrusion, and/or displacement 
of the BAG material were found. Statistical analyses revealed signifi-
cant hearing improvement. Mestdagh et al. [11] investigated the efficacy 
of S53P4 as filler material in 67 cholesteatoma patients who received 
mastoid obliteration surgery. An acceptably dry ear was achieved in 
96% of all cases. Silvola et al. [15] reported a case series of 14 patients 
who underwent mastoidectomy and cavity obliteration with S53P4. All 
the ears became dry and one ear was overfilled and required meato-
plasty. Sarin et al. [17] presented a retrospective case series that included 
26 patients. Excluding two patients with only 1 month of follow-up, 
96% of the cases had a dry, safe ear or only intermittent ear discharge. 
In 92% of the patients, a smaller or nonexistent cavity was achieved. 
Stoor et al. [20] treated six patients with radical cavities by using BAG 
S53P4 as a filling material. The mastoid cavities decreased in size in all 
cases. None of the patients had infections associated with BAG.
Regarding the use of BAG 45S5, the existing reports are quite posi-
tive. Ezzata and Eid performed a retrospective observational study 
with 40 patients. Postoperative ear discharge was found in only six 
patients (15%) and recurrence or residual cholesteatoma was found 
in four cases (10%) [14]. Shorky et al. [16] evaluated BAG 45S5 in 20 pa-
tients, where infection occurred in two cases but was readily con-
trolled by topical application of antibiotics.
Although hydroxyapatite is the second most widely used filler material 
for mastoid obliteration, its use does not seem to yield good results. In 
contrast to BAG, the overall incidence of extrusion was found to be 15.8%. 
Park et al. [19] examined the rate of graft failure and complications in three 
groups of patients sorted according to the graft material (autogenous 
bone, allogeneic bone, and HA). The rate of graft failure was 20% in HA 
group, 3.1% in allogenic bone group, and 0.8% in the autogenous bone 
group. Ridenour et al. [22] reported that the use of hydroxyapatite cement 
as an obliteration material in three pediatric patients was associated with 
disappointing outcomes, as all three cases required revision surgery to 
remove the HA cement. According to Kakigi et al. [21], calcium phosphate 
paste covered with artificial dermis and soaked with b-FGF was likely to 
be useful for the management of an open mastoid cavity. All 10 patients 
in their study demonstrated decreased volume of the mastoid bowl 
within two months without any recurrent discharge. Lee et al. [7] assessed 
the effectiveness of β-tricalcium phosphate and polyphosphate (β-TPP) 
as a mastoid filler in 20 patients with chronic otitis media by performing 
intact canal wall mastoidectomy or simple mastoidectomy. No bone re-
sorption was demonstrated in the obliterated mastoids.
Cho et al. [18] were the only authors who evaluated the efficacy of 
mastoid obliteration with silicone blocks. They performed a retro-
spective evaluation of 20 patients. In 19 cases (95%), the postoper-
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ative appearance of external auditory canal was found to be smooth 
and the tympanic membrane healed without perforation. In only 
one case (5%), the rebuilt canal wall was destroyed due to tympanic 
membrane perforation. Statistical analyses revealed significant im-
provement in hearing. 
Elbary et al. [10] were the only authors who used titanium mesh and 
platelet-rich plasma mixed with bone pate for the reconstruction of 
PMW. All patients showed apparently normal PMW contour. No com-
plications were reported.
Generally, most of the identified studies included a small number of 
enrolled patients and were of retrospective in nature. Additionally, the 
follow-up period was usually short, with the surgical outcomes being as-
sessed by the surgeons themselves. These factors carry a significant level 
of bias and conclusions should be interpreted very cautiously, particular-
ly when it comes to potential complications, the lack of which in some 
studies has made the scientific community wary. We cannot comment 
on the use of autologous materials, as this was not our goal.
CONCLUSION
Mastoid obliteration with synthetic materials seems to be a safe and 
effective therapeutic option for the management of an open mastoid 
cavity. BAG is the most researched and most reliable synthetic material 
for mastoid obliteration. HA carries the highest risk for a foreign body 
reaction. Finally, given the low level of evidence, prospective studies 
with a long follow-up and a more robust setting are required to look 
into synthetic and biological materials for mastoid obliteration.
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